Document is current

Article History

Received: 2 February 2024

Revised: 24 October 2024

Accepted: 28 October 2024

First Online: 14 November 2024

Declarations

:

: The GATHER1 trial was performed in accordance with the tenets of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines []. The appropriate ethics committee or institutional review board at each study center involved in the study (80 centers) approved the protocol [].

: Written informed consent was obtained from all participants [].

: SriniVas R Sadda- although the author is the editor of the journal, there was no involvement with the peer review process for this article.

: GC has received lecture fees from Nidek. AK, SS, SL, SBV, FC, YA, and MGN have no financial disclosures. SR Sadda has consulted/advised for: Apellis Pharmaceuticals, Inc.; Amgen Inc.; AbbVie/Allergan, Inc.; Samsung Bioepis; Biogen; Boehringer Ingelheim; Iveric Bio; Novartis; Roche/Genentech; Bayer Healthcare Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Pfizer Inc.; Astellas; Nanoscope Therapeutics; Janssen Pharmaceuticals, Inc.; CenterVue, Inc.; Optos, Inc.; and Heidelberg Engineering; has received lecture fees/speakers bureau fees from: Heidelberg Engineering; Roche/Genentech; Novartis; and Optos, Inc.; and has received research equipment from: CenterVue, Inc.; Optos, Inc.; Carl Zeiss Meditec; Topcon Medical Systems, Inc.; Heidelberg Engineering; and Nidek Inc. SR Sadda, the corresponding author, is an editor of the journal; however, there was no involvement with the peer review process for this article. DD and LZ are former employees of Astellas, and DA is an employee of Astellas.